Clinical trialNo phase (not a drug trial)Withdrawn
A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis(SHR-1210-HLJ-009)
Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis: a Single-arm, Prospective Study
- Outcome
- Stopped earlyFailed to pass ethics committee review (Other)
- Phase
- No phase (not a drug trial)
- Status
- Withdrawn
- Study type
- Interventional
- Planned start
- 1 August 2020
- Planned end
- 1 August 2023
- Enrollment
- 0 participants
- Sites
- 0
- Primary outcomes
- 6-month PFS rate
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 4 October 2022
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a a single-arm, prospective study of Camrelizumab combined with ablation and chemotherapy for patients with Pancreatic cancer liver metastasis. The main purpose of this study is to evaluate the safety and tolerability of Camrelizumab combined with ablation and chemotherapy as a treatment of Pancreatic cancer liver metastasis.